Axsome Announces FDA Approval Of Auvelity For Treatment Of Major Depressive Disorder

Axsome Therapeutics, Inc. (AXSM) announced the FDA has approved AUVELITY extended-release tablets for the treatment of major depressive disorder in adults. The company noted that AUVELITY is the first and only rapid-acting oral medicine approved for the treatment of major depressive disorder with labeling of statistically significant antidepressant efficacy compared to placebo starting at one week. Axsome expects AUVELITY to be commercially available in the U.S. in the fourth quarter of 2022.

The FDA granted Breakthrough Therapy designation for AUVELITY in March 2019. The AUVELITY New Drug Application was evaluated by the FDA under Priority Review.

Shares of Axsome Therapeutics are up 20% in pre-market trade on Friday.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Russia's manufacturing activity grew at the fastest pace in three-and-a-half years in September, supported by increases in production and new orders, survey data from S&P Global showed on Monday. The factory Purchasing Managers' Index posted 52.0 in September, up from 51.7 in August. A score above... India's manufacturing sector growth slowed moderately in September but the overall growth remained robust, survey data published by S&P Global showed on Monday. The manufacturing Purchasing Managers' Index fell to 55.1 in September from 56.2 in August. The score was also below economists' forecast... Final manufacturing Purchasing Managers' survey results from the euro area and the UK are the major reports due on Monday. At 2.30 am ET, the Federal Statistical Office is scheduled to issue Swiss consumer price data for September. Inflation is forecast to remain unchanged at 3.5 percent.
Follow RTT